

Chinese Herbs: A Clinical Review of Astragalus, Ligusticum, and Schizandrae

by Steven Sinclair, N.D. L.Ac.

Abstract

Although Astragalus, Ligusticum and Schizandrae have a long history of medicinal use within the traditional Chinese system, only recently has the West begun to understand their pharmacological possibilities and clinical applications. Astragalus has demonstrated a wide range of immunopotentiating effects and has proven efficacious as an adjunct cancer therapy. Ligusticum, and its active components, have been investigated for enhancement of the immune system, treatment of ischemic disorders, and as an anti-inflammatory. Clinically, the hepato-protective and antioxidant actions of Schizandrae have proven beneficial in the treatment of chronic viral hepatitis.

Altern Med Rev 1998;3(5):338-344.

Introduction

Chinese medicinal herbs are increasingly the subjects of pharmacological research. As researchers identify and isolate the bioactive components, our understanding of their physiological, therapeutic, and clinical actions increases. Traditionally, these herbs have a history of safe and effective treatment of many diseases, and while classically prescribed in multi-herb combinations, analysis of single constituents allows us to better understand their individual pharmacological actions.

Astragalus membranaceus

Astragalus membranaceus is one of the important “Qi tonifying” or adaptogenic herbs from the Chinese materia medica. It has been prescribed for centuries for general debility, chronic illnesses, and to increase the overall vitality of the system. Currently, much of the pharmacological research is focused on its immune stimulating polysaccharides and other active ingredients from the plant, useful in treating immune deficiency conditions.

Traditional Indications: In the Chinese medical system, Astragalus affects both the spleen and the lung meridians. It is indicated for spleen deficiency symptoms such as diarrhea, fatigue, spontaneous sweating, and lack of appetite.¹ Astragalus tonifies the lungs and is used in cases of frequent colds and shortness of breath.¹ Other traditional indications include wasting disorders, night sweats,² chronic ulcerations and sores,¹ numbness and paralysis of the limbs, and edema.¹ Astragalus is classically prescribed in combination with other Chinese medicinal herbs depending on the desired therapeutic effect and the exact diagnosis.

Steven Sinclair, ND, is in private practice in Hagerstown, Maryland, specializing in acupuncture and Chinese medicine.
Correspondence address: Green Valley Health, 1305 Pennsylvania Ave, Hagerstown, MD 21742

Chemical Constituents: Astragalus contains the plant pigments: formononetin, astraisoflavan, astrapterocarpan, 2'-3'-dihydroxy-7,4'-dimethoxyisoflavone, and isoliquiritigenin.² Other major constituents include D- β -asparagine, calycosin, cycloastragenol, astragalosides I-VII, choline, betaine, kumatakenin, sucrose, glucuronic acid, β -sitosterol 1, and soyasaponin I. Astragalan, a polysaccharide fraction with a molecular weight between 20,000 and 25,000, has been extracted and researched in China for its ability to enhance the *in vitro* secretion of tumor necrosis factor.³ See Figure 1.

Immunotherapy: The use of recombinant interleukin-2 (rIL-2) in immunotherapy is limited by the toxicity associated with higher doses. Astragalus was given with 100 u/ml of rIL-2 versus 1,000 u/ml of rIL-2 alone in an *in vitro* study on murine renal carcinoma cells. The Astragalus-rIL-2 group had a tumor cell lysis rate of 88 percent versus 86 percent in the group with 1000 u/ml rIL-2 alone. This suggests a 10-fold potentiation in the *in vitro* antitumor activity of rIL-2 generated lymphokine-activated killer (LAK) cells.⁴ These results were confirmed in another study where Astragalus was shown to potentiate the LAK cell inducing activity of rIL-2 against a Hs294T melanoma cell line.

Astragalus membranaceus



Fifty u/ml of rIL-2 with Astragalus extract F3 was more effective than 500 u/ml rIL-2 alone (64% vs. 60%).⁵


A mixture of Astragalus and two other herbs was fed to mice at 9g/kg or 20g/kg for seven days. Thymus and splenic weight increased when compared to those in the control group. Serum IgG levels were raised 41-47 percent and the conversion percentage of lymphocytes was also elevated. The Astragalus herbal mixture increased resistance to the immunosuppressive effects of cyclophosphamide⁶ while stimulating macrophages to produce interleukin-6 and tumor necrosis factor.⁷

Viral myocarditis patients, when given an oral Astragalus extract, showed enhanced T3, T4 and T4/T8 cell ratios⁸ suggesting improved immune response. In mice infected with coxsackie B-3 virus, Astragalus inhibited viral replication in the myocardial tissue while improving abnormal myocardial electric activity.^{9,10}

Twenty-eight patients with systemic lupus erythematosus had significantly decreased natural killer cell activity when compared to normal controls. Pre-incubation of their peripheral blood mononuclear cells with Astragalus stimulated natural killer cell cytotoxicity in SLE patients and in healthy controls.¹¹

Astragalus has also demonstrated *in vitro* antibacterial activity against *Shigella*


Figure 1. Chemical structure of Astrapterocarpan.



*dysenteriae, Streptococcus hemolyticus, Diplococcus pneumonia, and Staphylococcus aureus.*²

Adjunct Cancer Therapy: One hundred and sixteen Chinese herbal formulas were screened and evaluated for their ability to ameliorate the toxic side-effects of anticancer agents. A formula including Astragalus and Ligusticum, Shi-Quan-Da-Bu-Tang, was selected as the most effective in stimulating hemopoietic factors and interleukin produc-

Figure 2. Chemical structure of Ligustilide.



tion. It was also shown to potentiate the activity of chemotherapeutic agents, inhibit recurrences, prolong survival time, and reduce the adverse toxicities of antineoplastic agents.¹²

Two randomized groups of mice received renal cell carcinoma implants. One group was treated intraperitoneally with 500 mg of Astragalus and *Ligusticum lucidum* daily for ten days. The other group received saline as a control. The cure rate in the Astragalus/Ligusticum group was 57 percent when the tumor load was 2×10^5 and 100 percent when the tumor load was 1×10^5 .¹³

In another study, 10 out of 12 small-cell lung cancer patients, including 4 with extensive disease, gained between 3 and 17 years of survival time when Chinese herbs such as Astragalus were included with chemotherapy and radiation.¹⁴

Cardiovascular Studies: Astragaloside IV was isolated and injected into 19 patients with congestive heart failure daily for two weeks. After two weeks symptoms of chest distress and dyspnea were alleviated in 15 of the 19 patients. Heart rate slowed from 88.21 ± 17.19 to 64.55 ± 13.06 beats/min ($P < 0.05$).¹⁵

Ninety-two patients with ischemic heart disease were treated with Astragalus. Not only did they get significant relief from angina, but also the effective rate of EKG improvement was 82.6 percent.¹⁶ In another study on angina pectoris, 20 patients were given Astragalus for two weeks and evaluated by echocardiogram. Cardiac output increased from 5.09 ± 0.21 to 5.95 ± 0.18 L/min ($P < 0.01$). Adenosine triphosphatase activity was not inhibited with Astragalus, unlike that of digitalis.¹⁷

The saponins contained in Astragalus were found to have a positive effect on the function of the heart through the inhibition of the formation of lipid peroxides in the myocardium as well as by decreasing blood coagulation.¹⁸

Nephritis: Astragalus proved effective against experimentally induced glomerulonephritis in rats, especially in treating proteinuria.² Rats given high doses of Astragalus

had less proteinuria and milder pathological tissue changes than the control group.¹

Male Infertility: The water extracts of 18 herbs were tested for their effect on sperm motility. Astragalus was the only one that demonstrated a significant stimulatory effect. Using a solution of 10 mg/ml, sperm motility was increased to 146.6 +/- 22.6% of control.¹⁹

Toxicity: The LD50 of Astragalus is approximately 40g/kg when administered by intraperitoneal injection. Overall it is very safe and doses as high as 100g/kg of the raw herb have been given to rats by lavage with no adverse effects.¹

Ligusticum wallichii

A member of the Umbelliferae family, *Ligusticum wallichii* is used in Chinese medicine for a variety of hematological disorders including ischemia and thrombosis. When combined with Astragalus, Ligusticum has demonstrated a notable immunopotentiating effect. Included in many classic Chinese formulations, it is also part of the Japanese and Korean herbal formularies.

Traditional Indications: Ligusticum's traditional actions include invigorating blood circulation, promoting the flow of Qi, dispelling wind, and alleviating pain. Classically it is prescribed for headaches, abdominal pain, arthralgias, and menstrual disorders that are due to blood stasis.²

Chemical Constituents: Ligusticum's active ingredients include an alkaloid,

tetramethylpyrazine, ferulic acid (a phenolic compound), chrysophanol, sedanoic acid, and 1-2 percent of essential oils such as ligustilide and butylphthalide.² See Figure 2.

Ligusticum wallichii



Ischemia: One hundred and fifty-eight subjects with transient ischemic attack were randomly divided into a Ligusticum group (111 cases) and an aspirin group (47 cases). The total effective rate in the Ligusticum group was 89.2 percent as compared to 61.7 percent in the aspirin group ($P < 0.01$). Ligusticum increased cerebral blood flow, accelerated the velocity of blood flow, dilated the spastic artery, and decreased peripheral arterial resistance.²⁰


In another study, Ligusticum was evaluated in the treatment of ischemic stroke. Injectable preparations were shown to improve brain microcirculation through inhibiting thrombus formation,

decreasing platelet aggregation, and improving blood viscosity. The effect of Ligusticum was the same or better than the controls of papaverine, dextran and aspirin-persantin.²¹

Antibacterial/Antifungal Effects: Ligusticum has demonstrated *in vitro* effects against several strains of pathogenic bacteria including *Pseudomonas aeruginosa*, *Shigella sonnei*, *Salmonella typhi*, and *Vibrio cholera*.¹ The essential oil components of Ligusticum (butylphthalide) have been shown to inhibit dermatophytes *in vitro*.²

Anti-inflammatory Properties: When given to guinea pigs with histamine/

Figure 3. Chemical structure of Schizandrin.



acetylcholine induced bronchospasm, Ligusticum was found to decrease plasma levels of thromboxane B₂, relax tracheal muscle, increase the forced expiratory volume, and inhibit the synthesis and release of thromboxane A₂ with no adverse side-effects. The total effective rate was 92 percent vs. 62 percent in the control group ($P < 0.01$).²² In a Japanese study, the active ingredients in Ligusticum, tetramethylpyrazine and ferulic acid, were found to have both significant anti-inflammatory and analgesic effects.²³

Toxicity: Ligusticum is prescribed in traditional Chinese decoctions at dosages up to 9 grams administered over several days. Overdose symptoms may include vomiting and dizziness.¹

Schizandrae chinensis

Schizandrae chinensis, a member of the Magnoliaceae family, has an extensive history of medical use in China. This herb's adaptogenic properties increase resistance to a wide range of physical, chemical, and emotional stresses while promoting improved

overall regulation of physiological processes. Experimental evidence suggests *Schizandrae* has hepato-protective abilities and functions as a potent antioxidant.

Traditional Indications: Classically, *Schizandrae* is commonly prescribed for patterns of lung and kidney deficiency. It is considered astringent in nature and is indicated in cases of chronic cough and dyspnea, diarrhea, night sweats, wasting disorders, irritability, palpitations, dream-disturbed sleep, and insomnia.¹

Chemical Constituents: Research into the active ingredients is primarily focused on the various lignans and essential oils contained in the dried fruits of *Schizandrae*. The major chemical constituents include schizandrin, deoxyschizandrin, schisanhenol, schizandrol, sesquicarene, β -chamigrene, citral, stigmasterol, and vitamins C and E.^{1,2} See Figure 3.

Hepatic Activity: Recent studies from China have found *Schizandrae* and its active components to be effective against viral and chemical induced hepatitis.²⁴ *Schizandrae* was shown to lower SGPT levels in patients with chronic viral hepatitis and decrease the hepatotoxicity of carbon tetrachloride in animals.²⁵ DDB, a synthetic analogue of Schizandrin, is used widely in China as a hepato-protective drug, and while highly effective at normalizing liver function, has very few side-effects.²⁶ Pharmacological studies on the bioactive lignans in *Schizandrae* found they increased liver protein and glycogen synthesis, inhibited carbon tetrachloride induced lipid peroxidation, and had an inducing effect on the cytochrome P-450 enzyme system.²⁶

In one study, powdered *Schizandrae* was administered to 102 patients with hepatitis. The overall success rate was 76 percent, and in cases where SGPT levels were over 300 U/L, the success rate was 72 percent. It took an average of twenty-five days for liver enzymes to return to normal with no adverse side-effects from the treatment.¹

Schizandrae chinensis



Antioxidant Potential: Seven of the nine lignans from *Schizandrae* were found to inhibit vitamin C/NADPH induced lipid peroxidation in rat liver microsomes. Of these compounds, schisanhenol and schizandrin were shown to be more effective than vitamin E at the same concentration. Schizandrins B and C were found to have strongest scavenging effect against active oxygen radicals.²⁷ When these compounds were given orally to mice at 15 ml/kg, there was significant reduction in ethanol induced malondialdehyde formation with increased superoxide dismutase and catalase activity.²⁸

Anti-bacterial Effect: Decoctions of *Schizandrae* were found to possess strong *in vitro* inhibitory action on *Bacillus subtilis*, *Bacillus dysenteriae*, *Bacillus typhi*, and *Staphylococcus aureus*.²

Dosage and Toxicity: Therapeutic dosages are 400-450 mg powdered herb in capsules three times daily or 1-2 ml of 1:3 EtOH tincture of *Schizandrae* three times daily. Toxic doses when orally administered to mice were approximately 10 to 15g/kg. Overdose symptoms include restlessness, insomnia and dyspnea.¹

Discussion

Although these herbs have a long history of medicinal use within the traditional Chinese system, it has been only recently in the West that we have begun to understand their pharmacological possibilities. *Astragalus* has a wide range of potential therapeutic applications in immunodeficiency syndromes,

as an adjunct cancer treatment, and for its adaptogenic effect on the heart and kidneys. *Ligusticum* has proven efficacious in treating ischemic disorders and its active ingredients are being researched for their anti-inflammatory properties. In cases of viral hepatitis, *Schizandrae* has demonstrated a hepato-protective effect, the ability to lower SGPT enzymes, and has significant antioxidant capabilities.

There are several inherent difficulties in researching Chinese medicinal herbs. Classic Chinese herbal prescriptions usually include between five and ten herbs per formula and contain hundreds of potentially active ingredients. They become difficult to evaluate using the Western pharmacological model of analyzing a solitary agent for a specific effect. Much of the research conducted on complex formulas was not included, as it did not fit the single herb focus of this article. Nevertheless, it is apparent that the medicinal effects of Chinese herbs, with their low toxicity and well-established traditional use, have many potential clinical and therapeutic applications in the Western medical setting.

References

1. Bensky D, Gamble A. *Chinese Herbal Medicine: Materia Medica, Revised Edition*. Seattle, WA: Eastland Press; 1993.
2. Hong YH. *Oriental Materia Medica: A Concise Guide*. Long Beach, CA: Oriental Healing Arts Institute; 1986.
3. Zhao KW, Kong HY. Effect of *Astragalus* on secretion of tumor necrosis factor in human peripheral mononuclear cells. *Chung Kuo Hsi I Chieh Ho Tsa Chih* 1993;13:263-265.

4. Wang Y, Qian XJ, Hadley HR, Lau BH. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. *Mol Biother* 1992;4:143-146.
5. Chu DT, Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in cancer and AIDS patients induced by F3-a fractionated extract of Astragalus membranaceus. *Chung Hua Chung Liu Tsa Chih* 1994;16:167-171.
6. He J, Li Y, Wei S, et al. Effect of mixture of Astragalus membranaceus, Fructus Ligusti lucidum and Eclipta prostrata on immune function in mice. *Hua Hsa I Ko Ta Hseuh Hseuh Pao* 1992;23:408-411.
7. Yoshida Y, Wang MQ, Shan BE, Yamashita U. Immunomodulating activity of Chinese medical herbs and Oldenlandia diffusa in particular. *Int J Immunopharmacol* 1997;19:359-370.
8. Huang ZQ, Qin NP, Ye W. Effect of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1995;15:328-330.
9. Peng T, Riesemann H, Kandolf R. The inhibitory effect of Astragalus membranaceus on coxsackie B3 virus RNA replication. *Chin Med Sci J* 1995;10:146-150.
10. Guo Q, Peng TQ, Yang YZ. Effect of Astragalus membranaceus on Ca²⁺ influx and coxsackie virus B3 replication in cultured neonatal rat heart cells. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1995;15:483-485.
11. Zhao XZ. Effects of Astragalus membranaceus and Tripterygium hypoglancum on natural killer cell activity of peripheral blood mononuclear cells in systemic lupus erythematosus. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1992;12:679-671.
12. Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. *Methods Find Exp Clin Pharmacol* 1992;14:725-736.
13. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. *Cancer Biother* 1994;9:153-161.
14. Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine. *Chung Hua Nei Ko Tsa Chih* 1994;33:462-466.
15. Luo HM, Dai RH, Li Y. Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1995;15:707-709.
16. Li SQ, Yuan RX, Gao H. Clinical observation on the treatment of ischemic heart disease with Astragalus membranaceus. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1995;15:77-80.
17. Lei ZY, Qin H, Liao JZ. Action of Astragalus membranaceus on left ventricular function of angina pectoris. *Chung Kuo Chung Hsi I Ho Chieh Ho Tsa Chih* 1994;14:199-202.
18. Purmova J, Opletal L. Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy. *Ceska Slov Farm* 1995;44:246-251.
19. Hong CY, Ku J, Wu P. Astragalus membranaceus stimulates human sperm motility in vitro. *Am J Chin Med* 1992;20:289-294.
20. Chen DR. Clinical and experimental study of Ligusticum wallichii and aspirin in the treatment of transient ischemic attack. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1992;12:672-674.
21. Chen KJ, Chen K. Ischemic stroke treated with Ligusticum chuanxiong. *Chin Med J* 1992;105:870-873.
22. Shao CR, Chen FM Tang YX. Clinical and experimental study on Ligusticum wallichii mixture in preventing and treating bronchial asthma. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1994;14:465-468.
23. Ozaki Y. Antiinflammatory effect of tetramethylpyrazine and ferulic acid. *Chem Pharm Bull* 1992;40:954-956.
24. Liu GT. Pharmacological actions and clinical use of fructus Schizandrae. *Chin Med J* 1989;102:740-749.
25. Liu KT, Lesca P. Pharmacological properties of dibenzo[a,c]cyclootene derivatives isolated from Fructus Schizandrae chinensis III. Inhibitory effects on carbon tetrachloride induced lipid peroxidation, metabolism and covalent binding of CCl₄ to lipids. *Chem Biol Interact* 1982;41:39-47.
26. Li XY. Bioactivity of neolignans from fructus Schizandrae. *Mem Inst Oswaldo Cruz* 1991;86:31-37.
27. Li XJ, Zhao BL, Liu GT, Xin WJ. Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations. *Free Radic Biol Med* 1990;9:99-104.
28. Lu H, Liu GT. Effect of dibenzo[a,c]cyclootene lignans isolated from fructus Schizandrae on lipid peroxidation and anti-oxidative enzyme activity. *Chem Biol Interact* 1991;78:77-84.